Literature DB >> 1986026

Daily cortisol production rate in man determined by stable isotope dilution/mass spectrometry.

N V Esteban1, T Loughlin, A L Yergey, J K Zawadzki, J D Booth, J C Winterer, D L Loriaux.   

Abstract

Growth retardation as well as the development of Cushingoid features in adrenally insufficient patients treated with the currently accepted replacement dose of cortisol (33-41 mumol/day.m2; 12-15 mg/m2.day) prompted us to reevaluate the cortisol production rate (FPR) in normal subjects and patients with Cushing's syndrome, using a recently developed thermospray liquid chromatography-mass spectrometry method. The stable isotope [9,12,12-2H3]cortisol was infused continuously for 31 h at about 5% of the anticipated FPR. Blood samples were obtained at 20-min intervals for 24 h, spun, and pooled in 4-h groups. Tracer dilution in plasma was determined by liquid chromatography/mass spectrometry. The method was validated with controlled infusions in 6 patients with adrenal insufficiency. Results from 12 normal volunteers revealed a FPR of 27.3 +/- 7.5 mumol/day (9.9 +/- 2.7 mg/day) or 15.7 mumol/day.m2; 5.7 mg/m2. day). A previously unreported circadian variation in FPR was observed. Patients with Cushing's syndrome demonstrated unequivocal elevation of FPR and cortisol concentration correlated during each sample period in normal volunteers, indicating that cortisol secretion, rather than metabolism, is mainly responsible for changes in plasma cortisol. Our data suggest that the FPR in normal subjects may be lower than previously believed.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1986026     DOI: 10.1210/jcem-72-1-39

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  72 in total

1.  Glucocorticoids in the treatment of early and late RA.

Authors:  J W J Bijlsma; M Boers; K G Saag; D E Furst
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

Review 2.  Adrenal insufficiency: etiology, diagnosis and treatment.

Authors:  Nicola Neary; Lynnette Nieman
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2010-06       Impact factor: 3.243

Review 3.  Diagnosis and treatment of ACTH deficiency.

Authors:  Mark S Cooper; Paul M Stewart
Journal:  Rev Endocr Metab Disord       Date:  2005-01       Impact factor: 6.514

4.  Tripartite control of dynamic ACTH-cortisol dose responsiveness by age, body mass index, and gender in 111 healthy adults.

Authors:  Johannes D Veldhuis; Ali Iranmanesh; Ferdinand Roelfsema; Paul Aoun; Paul Takahashi; John M Miles; Daniel M Keenan
Journal:  J Clin Endocrinol Metab       Date:  2011-07-13       Impact factor: 5.958

Review 5.  Endogenous subclinical hypercortisolism: Diagnostic uncertainties and clinical implications.

Authors:  S Tsagarakis; D Vassiliadi; N Thalassinos
Journal:  J Endocrinol Invest       Date:  2006-05       Impact factor: 4.256

Review 6.  [Adrenal crisis. Diagnostic and therapeutic management of acute adrenal cortex insufficiency].

Authors:  S Hahner; W Arlt; B Allolio
Journal:  Internist (Berl)       Date:  2003-10       Impact factor: 0.743

7.  Low bone mineral density in adults with previous hypothalamic-pituitary tumors: correlations with serum growth hormone responses to GH-releasing hormone, insulin-like growth factor I, and IGF binding protein 3.

Authors:  R G Bing-You; M C Denis; C J Rosen
Journal:  Calcif Tissue Int       Date:  1993-03       Impact factor: 4.333

Review 8.  Isolated corticotrophin deficiency.

Authors:  Massimiliano Andrioli; Francesca Pecori Giraldi; Francesco Cavagnini
Journal:  Pituitary       Date:  2006       Impact factor: 4.107

9.  Correction of cortisol overreplacement ameliorates morbidities in patients with hypopituitarism: a pilot study.

Authors:  Karina Danilowicz; Oscar Domingo Bruno; Marcos Manavela; Reynaldo Manuel Gomez; Ariel Barkan
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

10.  Selective inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 for patients with metabolic syndrome: is the target liver, fat, or both?

Authors:  Paul M Stewart; Jeremy W Tomlinson
Journal:  Diabetes       Date:  2009-01       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.